Moderna's cancer vaccine trials could pave way for shift in care

Moderna's stock fell Thursday, reducing its market cap by $18B after a record surge following positive cancer vaccine trial results. Co-founders and CEO saw significant net worth changes. Analysts view the trial as critical for Moderna's stock. The company's revenue is $145M with a net loss of $782M in the latest quarter, per the company.

Moderna's melanoma trial with mRNA-4157 and Merck's Keytruda met primary and secondary endpoints, prompting Jefferies to upgrade the stock to Neutral and raise its price target to $170. The firm expects significant peak sales for the therapy, though shares fell 17% after a prior rally.

Walmart (WMT) fell 9% as Q2 revenue beat estimates but same-store sales and EPS guidance missed. Deere (DE) rose 9% after Q3 earnings and revenue topped estimates, raising full-year guidance. Webull (WB) gained 4% with Q2 adjusted operating income and revenue beating expectations. Crypto-related stocks like Coinbase (COIN) and Mara Holdings (MARA) climbed 7-12% following Bitcoin and Ether's surge. Moderna (MRNA) plunged 25% after a 177% gain, as trial results for a skin cancer vaccine were met w

Moderna's stock fell 25% on Thursday, reducing its market value by $18 billion, after a 176% surge the previous day. The initial rise followed positive trial results for its cancer vaccine, developed with Merck's Keytruda. Analysts praised the results but noted further testing is needed. Moderna's market cap is now $51.5 billion. According to Bank of America, the results diversify Moderna's portfolio beyond infectious diseases.

A former Meta engineering director testified that the company prioritized profits over safety for underage users. Meta faces a trial with multiple states over these claims. The U.S. Treasury announced plans to double bond buybacks to calm rising yields. Moderna shares surged after positive cancer treatment trial results. Fed minutes suggest rate hikes may be needed if inflation persists. UAE suspended trade with Iran following missile attacks.

Moderna (MRNA) shares surged 177% after its mRNA cancer vaccine met Phase 3 trial goals with Merck's Keytruda, then fell 20% the next day. The vaccine showed a 49% reduction in recurrence or death in melanoma patients. Moderna has ongoing studies across multiple cancer types. Investors are reassessing the impact of the vaccine on the business.